Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Eggermont

Showing results (11-20 of 139) with videos related to

Pageof 14
Sort By:
European Journal of Cancer (Oxford, England : 1990)|February 19, 2018
European Academy of Cancer Sciences-Designation of Comprehensive Cancer Centres of ExcellenceUlrik Ringborg, Julio Celis, Alexander Eggermont, et al.
British Journal of Cancer|November 11, 2018
PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockadeLaure Hirsch, Laurence Zitvogel, Alexander Eggermont, et al.
Nature Cancer|February 5, 2022
Harnessing the microbiome to restore immunotherapy responseSusan Bullman, Alexander Eggermont, Christopher D Johnston, et al.
Oncoimmunology|April 11, 2014
Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumorsAlexander Eggermont, Caroline Robert, Jean Charles Soria, et al.
Critical Reviews in Immunology|June 19, 2014
Tumor plasticity interferes with anti-tumor immunitySalem Chouaib, Bassam Janji, Andres Tittarelli, et al.
Cancer Treatment Reviews|August 21, 2003
Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trialsKeith Wheatley, Natalie Ives, Barry Hancock, et al.
Oncoimmunology|March 8, 2014
Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacyStéphane Champiat, Charles Ferté, Sophie Lebel-Binay, et al.
Oncoimmunology|July 4, 2012
Trial Watch: Immunostimulatory cytokinesErika Vacchelli, Lorenzo Galluzzi, Alexander Eggermont, et al.
Molecular Oncology|February 28, 2019
Boosting the social impact of innovative cancer research - towards a mission-oriented approach to cancerUlrik Ringborg, Julio E Celis, Michael Baumann, et al.
Oncoimmunology|February 1, 2014
Trial Watch: Lenalidomide-based immunochemotherapyMichaela Semeraro, Erika Vacchelli, Alexander Eggermont, et al.
Pageof 14

Showing results (11-20 of 139) with videos related to

Sort By:
Pageof 14
European Journal of Cancer (Oxford, England : 1990)|February 19, 2018
European Academy of Cancer Sciences-Designation of Comprehensive Cancer Centres of ExcellenceUlrik Ringborg, Julio Celis, Alexander Eggermont, et al.
British Journal of Cancer|November 11, 2018
PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockadeLaure Hirsch, Laurence Zitvogel, Alexander Eggermont, et al.
Nature Cancer|February 5, 2022
Harnessing the microbiome to restore immunotherapy responseSusan Bullman, Alexander Eggermont, Christopher D Johnston, et al.
Oncoimmunology|April 11, 2014
Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumorsAlexander Eggermont, Caroline Robert, Jean Charles Soria, et al.
Critical Reviews in Immunology|June 19, 2014
Tumor plasticity interferes with anti-tumor immunitySalem Chouaib, Bassam Janji, Andres Tittarelli, et al.
Cancer Treatment Reviews|August 21, 2003
Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trialsKeith Wheatley, Natalie Ives, Barry Hancock, et al.
Oncoimmunology|March 8, 2014
Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacyStéphane Champiat, Charles Ferté, Sophie Lebel-Binay, et al.
Oncoimmunology|July 4, 2012
Trial Watch: Immunostimulatory cytokinesErika Vacchelli, Lorenzo Galluzzi, Alexander Eggermont, et al.
Molecular Oncology|February 28, 2019
Boosting the social impact of innovative cancer research - towards a mission-oriented approach to cancerUlrik Ringborg, Julio E Celis, Michael Baumann, et al.
Oncoimmunology|February 1, 2014
Trial Watch: Lenalidomide-based immunochemotherapyMichaela Semeraro, Erika Vacchelli, Alexander Eggermont, et al.
Pageof 14